| Identification | Back Directory | [Name]
4-((4-ethylpiperazin-1-yl)Methyl)-3-(trifluoroMethyl)aniline | [CAS]
630125-91-6 | [Synonyms]
4-((4-ethylpiperazin-1-yl)Methyl)-3-(trifluoroMethyl)aniline
4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)aniline
Benzenamine, 4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- | [Molecular Formula]
C14H20F3N3 | [MDL Number]
MFCD09909923 | [MOL File]
630125-91-6.mol | [Molecular Weight]
287.32 |
| Chemical Properties | Back Directory | [Boiling point ]
344.9±42.0 °C(Predicted) | [density ]
1.195±0.06 g/cm3(Predicted) | [storage temp. ]
under inert gas (nitrogen or Argon) at 2–8 °C | [solubility ]
soluble in Dichloromethane; | [form ]
Solid | [pka]
7.76±0.10(Predicted) | [color ]
Yellow |
| Hazard Information | Back Directory | [Uses]
4-[(4-Ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)-benzenamine is one of the key reactants with N-[1-(4-Aminophenyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]benzamide used in the synthesis of a pyrrolo[3,2-c]pyridine derivative [N-[1-[4-[[[[4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]-1H-pyrrolo[3,2-c]pyridin-4-yl]benzamide (I)], an anticancer diarylurea derivative with multiple-kinase inhibitory effect; Also, it is an intermediate used in the synthesis of N-[4-[(4-Ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-N''-[4-[[6-(methylamino)-4-pyrimidinyl]oxy]phenyl]urea (E926495), which is an inhibitor of RET, FLT3, KDR, c-Abl and c-Kit. Also, it prevent the growth of human thyroid cancer cells. | [Synthesis]
1-Ethyl-4-(4-nitro-2-(trifluoromethyl)benzyl)piperazine (21.7 g, 68.3 mmol) was used as starting material, which was dissolved in methanol and stirred thoroughly. Pd/C catalyst (1.8 g, 17.08 mmol) was added to the reaction system and the reaction was stirred at room temperature under hydrogen atmosphere for about 12 hours. Upon completion of the reaction, the reaction mixture was filtered through a diatomite pad under reduced pressure and the diatomite pad was washed with methanol. The filtrate was collected and concentrated under reduced pressure to afford the target product 4-(4-ethylpiperazine-1-methyl)-3-trifluoromethylaniline (19.4 g, 99% yield). The product was confirmed by NMR hydrogen spectrum (300 MHz, DMSO-d6): δ 7.30 (d, 1H), 6.85 (s, 1H), 6.76 (d, 1H), 5.42 (s, 2H), 3.37 (s, 2H), 2.33 (m, 10H), 1.01 (t, 3H). Mass spectrometry analysis (ESI+, m/z): 288 [M+H]+. | [References]
[1] Patent: WO2013/100632, 2013, A1. Location in patent: Page/Page column 37
[2] Patent: US2014/371219, 2014, A1. Location in patent: Paragraph 0249; 0250; 0251
[3] Patent: EP2876107, 2015, A1. Location in patent: Paragraph 0090
[4] Patent: US2015/191450, 2015, A1. Location in patent: Paragraph 0191-0193
[5] Patent: WO2014/206343, 2014, A1. Location in patent: Page/Page column 81 |
|
| Company Name: |
Cochemical Ltd.
|
| Tel: |
029-86115547 17791676824 |
| Website: |
http://www.cochemical.com |
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
Rhawn Reagent
|
| Tel: |
400-400-1332688 18019345275 |
| Website: |
http://www.rhawn.cn |
|